453 related articles for article (PubMed ID: 8497875)
1. OKT3 for primary therapy of the first rejection episode in kidney transplants.
Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
[TBL] [Abstract][Full Text] [Related]
2. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
[TBL] [Abstract][Full Text] [Related]
3. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
[TBL] [Abstract][Full Text] [Related]
4. The UNOS Scientific Renal Transplant Registry--ten years of kidney transplants.
Cecka JM
Clin Transpl; 1997; ():1-14. PubMed ID: 9919387
[TBL] [Abstract][Full Text] [Related]
5. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
[TBL] [Abstract][Full Text] [Related]
6. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
[TBL] [Abstract][Full Text] [Related]
7. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. United Network for Organ Sharing.
Sarwal MM; Cecka JM; Millan MT; Salvatierra O
Transplantation; 2000 Dec; 70(12):1728-36. PubMed ID: 11152105
[TBL] [Abstract][Full Text] [Related]
8. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous quadruple immunosuppression with cyclosporine induction therapy in high risk renal transplant recipients.
Indudhara R; Khauli RB; Menon M; Stoff JS
J Urol; 1994 Aug; 152(2 Pt 1):307-11. PubMed ID: 8015058
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study.
Opelz G
Transplantation; 1995 Dec; 60(11):1220-4. PubMed ID: 8525514
[TBL] [Abstract][Full Text] [Related]
13. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants.
Gulanikar AC; MacDonald AS; Sungurtekin U; Belitsky P
Transplantation; 1992 Feb; 53(2):323-8. PubMed ID: 1738926
[TBL] [Abstract][Full Text] [Related]
14. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection.
Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ
Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115
[TBL] [Abstract][Full Text] [Related]
15. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
Schulak JA; Mayes JT; Moritz CE; Hricik DE
Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
Stegall MD; Simon M; Wachs ME; Chan L; Nolan C; Kam I
Transplantation; 1997 Dec; 64(12):1695-700. PubMed ID: 9422404
[TBL] [Abstract][Full Text] [Related]
18. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
19. Effect of OKT3 in steroid-resistant renal transplant rejection.
Petrie JJ; Rigby RJ; Hawley CM; Suranyi MG; Whitby M; Wall D; Hardie IR
Transplantation; 1995 Feb; 59(3):347-52. PubMed ID: 7871563
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
